25 research outputs found
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/102721/1/ejhfhfp136.pd
Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142515/1/ejhf937.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142515/2/ejhf937_am.pd
Diabetes Worsens Skeletal Muscle Mitochondrial Function, Oxidative Stress, and Apoptosis After Lower-Limb Ischemia-Reperfusion: Implication of the RISK and SAFE Pathways?
Objectives: Diabetic patients respond poorly to revascularization for peripheral arterial disease (PAD) but the underlying mechanisms are not well understood. We aimed to determine whether diabetes worsens ischemia-reperfusion (IR)-induced muscle dysfunction and the involvement of endogenous protective kinases in this process.Materials and Methods: Streptozotocin-induced diabetic and non-diabetic rats were randomized to control or to IR injury (3 h of aortic cross-clamping and 2 h of reperfusion). Mitochondrial respiration, reactive oxygen species (ROS) production, protein levels of superoxide dismutase (SOD2) and endogenous protective kinases (RISK and SAFE pathways) were investigated in rat gastrocnemius, together with upstream (GSK-3β) and downstream (cleaved caspase-3) effectors of apoptosis.Results: Although already impaired when compared to non-diabetic controls at baseline, the decline in mitochondrial respiration after IR was more severe in diabetic rats. In diabetic animals, IR-triggered oxidative stress (increased ROS production and reduced SOD2 levels) and effectors of apoptosis (reduced GSK-3β inactivation and higher cleaved caspase-3 levels) were increased to a higher level than in the non-diabetics. IR had no effect on the RISK pathway in non-diabetics and diabetic rats, but increased STAT 3 only in the latter.Conclusion: Type 1 diabetes worsens IR-induced skeletal muscle injury, endogenous protective pathways not being efficiently stimulated
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial
To test the hypothesis that an earlier post-acute myocardial infarction
(AMI) eplerenone initiation in patients with left ventricular systolic
dysfunction (LVSD) and heart failure (HF) is associated with better
long-term outcomes.
The 6632 patients of the EPHESUS study were randomized from day 3 to 14
after the index AMI (median = 7 days), of these 3319 were assigned to
eplerenone. We analysed the differential effects of time-to-eplerenone
initiation vs. placebo, based on the median time to initiation of
treatment (< 7 days-’earlier’, >= 7days-’later’). Effects on outcomes
were evaluated over a mean 16-month follow-up, using Cox proportional
hazards regression analysis. The earlier eplerenone initiation (< 7
days) reduced the risk of all-cause mortality by 31% (P = 0.001) when
compared with the ‘earlier’ placebo’ and also reduced the risks of
cardiovascular (CV) hospitalization/CV mortality by 24% (P < 0.0001)
and sudden cardiac death (SCD) by 34% (P < 0.0001). In contrast, later
eplerenone initiation (>= 7 days) had no significant effect on outcomes.
Interactions between time-to-randomization and treatment were
significant. These associations remained substantially unchanged after
risk adjustment in multivariable models.
An earlier eplerenone administration (3-7days) post-AMI improved
outcomes in patients with LVSD and HF. This benefit was not observed
when eplerenone was initiated later (>= 7days)
Features of Cardiac Remodeling, Associated With Blood Pressure and Fibrosis Biomarkers, Are Frequent in Subjects With Abdominal ObesityNovelty and Significance
International audienceIncidence and prevalence of abdominal obesity (AO) are growing exponentially. Subjects with AO are at higher risk of developing heart failure. The purpose of the study was to investigate early changes in cardiac and arterial structure and function and extracellular matrix biomarkers in normotensive healthy subjects with AO. Subjects with AO and age- and sex-matched controls underwent echocardiography, MRI (cardiac remodeling index), carotid intima-media thickness, pulse wave velocity, and blood fibrosis biomarkers measurements. We enrolled 87 subjects with AO and 53 controls. Although normotensive, subjects with AO had higher systolic blood pressure (BP; 122±11 versus 116±11 mm Hg; P=0.003), left ventricular mass (94±24 versus 84±21 g; P=0.034), and cardiac remodeling index (0.67±0.16 versus 0.60±0.10 g/mL; P=0.026) but unchanged carotid intima-media thickness and pulse wave velocity. Diastolic dysfunction (E' <10 cm/s) could be detected in 38% of subjects with AO (4% in controls). Left ventricular remodeling, as assessed by cardiac remodeling index, was positively and independently associated with higher BP (systolic BP and mean arterial pressure but not diastolic BP) and AO. Higher BP, AO, and procollagen-III-N-terminal peptide (≥2.4 ng/mL) concentrations (odds ratio, 4.15 [1.42-12.2]; P=0.01) were positively associated with diastolic dysfunction. Early cardiac structural remodeling, fibrosis, and diastolic dysfunction were detectable in healthy subjects with AO. Higher BP, procollagen-III-N-terminal peptide, and AO were independently associated with early cardiac structural and functional changes. It is to be investigated whether in subjects with AO, an early BP reduction, even if normotensive, combined with weight loss may avoid adverse cardiac remodeling and protect against progression to heart failure
Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report
Abstract Background Primary cardiac lymphomas (PCL) represent extremely rare cardiac tumors which are accompanied by poor prognosis, unless they are timely diagnosed and treated. Case presentation Herein we present a 28-year-old, immunocompetent man who presented to our hospital due to progressively worsening symptoms and signs of superior vena cava syndrome. Multi-modality imaging demonstrated a large intracardiac tumor, which was proven, by biopsy, to be a PCL. The patient received targeted chemotherapy which led to total remission of his disease, with no relapse over a 15-month follow-up period. Conclusions Although PCLs are rare, they should always be kept in mind in the differential diagnosis of cardiac tumors. Timely diagnosis of PCLs and appropriate chemotherapy, alone or in combination with radiotherapy, seems to provide the best results
Diabetes Worsens Skeletal Muscle Mitochondrial Function, Oxidative Stress, and Apoptosis After Lower-Limb Ischemia-Reperfusion: Implication of the RISK and SAFE Pathways?
International audienc